Switzerland
Galventa AG is a biotechnology, health care, and manufacturing startup founded in 2018 and headquartered in Switzerland. The company's slogan of "Empower people to perform every day at their best – from the very moment they wake up" encapsulates its mission to improve sleep and waking-up through innovative galenic platform technologies.
The company's flagship product, B・SYNC ON, is a dietary supplement designed to synchronize the circadian rhythm, enabling individuals to transition from being "night owls" to "early birds." This product is especially targeted at individuals who find it challenging to perform well in the early hours of the day due to misalignment between their biological clock and lifestyle.
In 2023, Galventa received a grant investment from Innosuisse, signifying confidence in its innovative galenic formulations. The company has also filed for a nutraceutical patent, covering technical, process-related, and application-based aspects, supported by favorable clinical trial results. Anticipating the grant of this patent, Galventa is exemplifying a strong potential for growth and impact in the health and wellness industry.
